Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript

Pushkal Garg: Yes. Thanks, Whitney, for your question about APP. It’s a program that we’re incredibly excited about. The data that we shared last year really suggested that we can have pretty profound impacts on the protein, on amyloid precursor protein, as well as the downstream isoforms of AB40 and AB42 that are involved in both Alzheimer’s disease and CAA. We have the Part B that’s ongoing and we hopefully will show ongoing data with regards to knockdown safety as well as imaging and biomarker data. So look for that as something we’re also going to be initiating our CAA studies soon. We’re very excited about the opportunity that’s the second leading cause of hemorrhagic stroke major with really no available treatments for these patients.

And we think that lowering APP could be beneficial in that disease. We’ll be kicking off a Phase 2 shortly, and we’ve also announced that we plan to kick off a Alzheimer’s disease study at or around year end of this year. So this is a really exciting program. And then, it allows us then with our colleagues at Regeneron to move forward a number of other programs in the CNS space. So thanks for your question. Lots of excitement there.

Christine Lindenboom: Great. Thank you Pushkal, and thank you everyone for joining us on the call. We’re really proud of our strong start to 2024. We’ve delivered robust commercial growth and exciting pipeline progress and we look forward to executing on the remainder of our 2024 goals. Our path to becoming a top tier biotech company. So thanks everyone and have a great day.

Operator: Thank you everyone for your participation in today’s conference. This does conclude and you may now disconnect.